SEYSARA
Drug
Almirall LLC
Total Payments
$1.4M
Transactions
574
Doctors
104
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $747,905 | 103 | 57 |
| 2019 | $518,048 | 312 | 70 |
| 2018 | $84,718 | 159 | 29 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $921,729 | 7 | 68.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $212,104 | 205 | 15.7% |
| Consulting Fee | $150,373 | 91 | 11.1% |
| Travel and Lodging | $49,910 | 156 | 3.7% |
| Food and Beverage | $16,554 | 115 | 1.2% |
Payments by Type
Research
$921,729
7 transactions
General
$428,941
567 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| SEYSARA IN THE TREATMENT OF ROSACEA | Almirall LLC | $322,373 | 0 |
| THE USE OF Sarecycline IN THE TREATMENT OF ROSACEA | Almirall LLC | $322,373 | 0 |
| Mode of action of sarecycline on the bacterial ribosome | Almirall LLC | $236,984 | 0 |
| ROLE OF ANTIBIOTICS IN THE TREATMENT OF ACNE VULGARIS | Almirall LLC | $40,000 | 0 |
Top Doctors Receiving Payments for SEYSARA — Page 5
Ad
Manufacturing Companies
- Almirall LLC $1.4M
Product Information
- Type Drug
- Total Payments $1.4M
- Total Doctors 104
- Transactions 574
About SEYSARA
SEYSARA is a drug associated with $1.4M in payments to 104 healthcare providers, recorded across 574 transactions in the CMS Open Payments database. The primary manufacturer is Almirall LLC.
Payment data is available from 2018 to 2020. In 2020, $747,905 was paid across 103 transactions to 57 doctors.
The most common payment nature for SEYSARA is "Unspecified" ($921,729, 68.2% of total).
SEYSARA is associated with 4 research studies, including "SEYSARA IN THE TREATMENT OF ROSACEA" ($322,373).